Evidence map›Paper›PMID 31662327›Full record

ArticleCancer research2020

Metastatic Conditioning of Myeloid Cells at a Subcutaneous Synthetic Niche Reflects Disease Progression and Predicts Therapeutic Outcomes.

Robert S Oakes, Grace G Bushnell, Sophia M Orbach, Pridvi Kandagatla, Yining Zhang, Aaron H Morris, Matthew S Hall, Petrina LaFaire, Joseph T Decker, Rachel M Hartfield and 4 more

Open access · greenAbstract readComment
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 39 citations in OpenAlex.

  1. Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. An engineered niche delineates metastatic potential of breast cancer.Bioengineering & translational medicine · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Robert S OakesDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-3783-6488
Grace G BushnellDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Sophia M OrbachDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Pridvi KandagatlaDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.
Yining ZhangDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan.
Aaron H MorrisDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Matthew S HallDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Petrina LaFaireMedical School, University of Michigan, Ann Arbor, Michigan.
Joseph T DeckerDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Rachel M HartfieldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-7112-6565
Michael D BrooksDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Max S WichaDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Jacqueline S JerussDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan. ldshea@umich.edu jjeruss@med.umich.edu.
Lonnie D SheaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan. ldshea@umich.edu jjeruss@med.umich.edu.
University of Michigan · USHenry Ford Health System · US

Funding

Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
University of Michigan Surgical Oncology Research Training ProgramT32CA009672 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JACQUELINE SARA JERUSS, WEIPING ZOU · 1991 to 2026
$6.0M
Postdoc Stipend Supplement: Developmental Origins of Metabolic Disorders T32T32DK071212 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON, Kanakadurga Singer · 2005 to 2026
$5.4M
An in vivo metastasis sensorR01CA173745 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BACKMAN, VADIM, SHEA, LONNIE D · 2012 to 2016
$4.2M
SHORT-TERM TRAINING IN HEALTH PROF SCHOOLST35HL007690 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLAHERTY, KEVIN R · 1990 to 2024
$3.3M
Identifying intercellular circuits driving cell phenotypes within a nicheR01CA243916 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JERUSS, JACQUELINE SARA, SHEA, LONNIE D · 2019 to 2023
$2.3M
Measuring Signaling Pathway Dynamics During Tissue Growth in HydrogelsR01CA214384 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JERUSS, JACQUELINE SARA, SHEA, LONNIE D · 2017 to 2021
$1.8M
Heterogeneity of the Early Metastatic Niche in Cancer Progression and ChemoresistanceF32CA243421 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ORBACH, SOPHIA M · 2019 to 2021
$194k
Engineering Natural Killer Cell Homing and Activation at the Metastatic NicheF32CA228262 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HALL, MATTHEW STEVEN · 2018 to 2020
$163k
Heterogeneity of early metastatic tumor cellsF31CA224982 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BUSHNELL, GRACE GILMORE · 2018 to 2019
$56k
NCI NIH HHS F31 CA224982NCI NIH HHS F32 CA228262NCI NIH HHS F32 CA243421NCI NIH HHS R01 CA173745NCI NIH HHS R01 CA214384NCI NIH HHS R01 CA243916NCI NIH HHS T32 CA009672NHLBI NIH HHS T35 HL007690NIDCR NIH HHS T32 DE007057NIDDK NIH HHS T32 DK071212
6 · The paper itself

Abstract

Monitoring metastatic events in distal tissues is challenged by their sporadic occurrence in obscure and inaccessible locations within these vital organs. A synthetic biomaterial scaffold can function as a synthetic metastatic niche to reveal the nature of these distal sites. These implanted scaffolds promote tissue ingrowth, which upon cancer initiation is transformed into a metastatic niche that captures aggressive circulating tumor cells. We hypothesized that immune cell phenotypes at synthetic niches reflect the immunosuppressive conditioning within a host that contributes to metastatic cell recruitment and can identify disease progression and response to therapy. We analyzed the expression of 632 immune-centric genes in tissue biopsied from implants at weekly intervals following inoculation. Specific immune populations within implants were then analyzed by single-cell RNA-seq. Dynamic gene expression profiles in innate cells, such as myeloid-derived suppressor cells, macrophages, and dendritic cells, suggest the development of an immunosuppressive microenvironment. These dynamics in immune phenotypes at implants was analogous to that in the diseased lung and had distinct dynamics compared with blood leukocytes. Following a therapeutic excision of the primary tumor, longitudinal tracking of immune phenotypes at the implant in individual mice showed an initial response to therapy, which over time differentiated recurrence versus survival. Collectively, the microenvironment at the synthetic niche acts as a sentinel by reflecting both progression and regression of disease. SIGNIFICANCE: Immune dynamics at biomaterial implants, functioning as a synthetic metastatic niche, provides unique information that correlates with disease progression. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/3/602/F1.large.jpg.

Indexed as

Biocompatible MaterialsNeoplasm Recurrence, LocalAnimalsCoalDisease ProgressionMiceTreatment OutcomeTumor MicroenvironmentBiocompatible MaterialsCoal

Identifiers

PMID31662327
PMCPMC7002274
OpenAlexW2982489381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.